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Abstract 
 
Zebrafish, Danio rerio, is increasingly used as an animal model to study the effects of 
pharmaceuticals and environmental estrogens. As most of these estrogens have only been tested 
on human estrogen receptors (ERs), it is necessary to measure their effects on zebrafish ERs. In 
humans there are two distinct nuclear ERs (hERα and hERβ), whereas the zebrafish genome 
encodes three ERs, zfERα and two zfERβ (zfERβ1 and zfERβ2). In this study, we established 
HeLa-based reporter cell lines stably expressing each of the three zfERs. We first reported that 
estrogens more efficiently activate the zfERs at 28oC as compared to 37oC, thus reflecting the 
 
physiological temperature of zebrafish in wildlife. We then showed significant differences in the 
ability of agonist and antagonist estrogens to modulate activation of the three zfERs isotypes in 
comparison to hERs. Environmental compounds (bisphenol A, alkylphenols, mycoestrogens) 
which are hERs panagonists and hERβ selective agonists displayed greater potency for zfERα as 
compared to zfERβs. Among hERα selective synthetic agonists, PPT did not activate zfERα 
while 16α-LE2 was the most zfERα selective compound. Altogether, these results confirm that all 
hER ligands control in a similar manner the transcriptional activity of zfERs although significant 
differences in selectivity were observed amongst subtypes. The zfER subtype selective ligands 
that we identified thus represent new valuable tools to dissect the physiological roles of the 
differents zfERs. Finally, our work also points out that care has to be taken in transposing the 
results obtained using the zebrafish as a model for human physiopathology. 
 
 
Keywords: Estrogen receptors, zebrafish, selective estrogens, endocrine disruptors, reporter cell 
lines 
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Abbreviations : hERs, human estrogen receptors; zfERs, zebrafish estrogen receptors; AF, 
transactivation function ; LBD, ligang binding domain; EDCs, endocrine disrupting chemicals; 
E2, 17β-Estradiol; 17α-E2, 17α-Estradiol ; E1, estrone; E3, estriol; EE2, 17α-ethynylestradiol; 
BP2, benzophenone-2; PPT, 4,4’,4’’-(4-Propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol; DPN, 2,3- 
bis(4-hydroxyphenyl)-propionitrile; WAY200070, (7-Bromo-2-(4-hydroxyphenyl)-1,3- 
benzoxazol-5-ol); FERB033 (2-Chloro-3'-fluoro-3,4'-dihydroxy-[1,1-biphenyl]-4-carboxaldehyde 
oxime); ERB041, (7-Ethenyl-2-(3-fluoro-4-hydroxyphenyl)-5-benzoxazolol); MPP 
dihydrochloride, (1,3-Bis(4-hydroxyphenyl)-4-methyl-5--[4-(2-piperidinylethoxy)phenol]-1H- 
pyrazole         dihydrochloride);         PHTPP,         (1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2- 
piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride); 4OH-Tam, 4-Hydroxytamoxifen; ICI 
 
182,780, (7α,17β-[9[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol); 
16α-LE2, 3,17-Dihydroxy-19-nor-17α-pregna-1,3,5(10)-triene-21,16α-lactone; 8β-VE2, 8- 
vinylestra-1,3,5(10)-triene-3,17β-diol, 
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Introduction 
 
 
Estrogens play critical roles in various physiological processes during development and adult life 
in vertebrates. In mammals, these effects are mediated by members of the nuclear receptor 
superfamily, the estrogen receptors ERα and ERβ (Green et al. 1986; Kuiper et al. 1987). These 
receptors share a common structural architecture composed of three functional domains. The A/B 
(or NH2-terminal domain) is involved in transcriptional activation of gene expression; the C or 
DNA-binding domain contains a two zinc finger structure, which is important for receptor 
dimerization and binding of receptors to specific DNA sequences; the E/F or COOH-terminal 
domain mediates ligand binding, receptor dimerization, nuclear translocation and transactivation 
of target gene expression in association with coactivators and corepressors (Nilsson et al. 2001). 
The transactivation functions of both the A/B (AF-1) and the E/F (AF-2) domains are dependent 
on the cell type and promoter context (Berry et al. 1990). Some ER subtype-selective ligands 
have been identified, which have different binding affinities for the two estrogen receptors and 
present variable agonistic or antagonistic characters depending on the ER considered (Delfosse et 
al. 2012; Escande et al. 2006; Molina-Molina et al. 2008). Dissimilarities in the N-terminal and 
ligand bindind domain (LBD) regions of ERα and ERβ explain the differences between the two 
receptors in their response to various ligands (Matthews et al. 2003; Ogawa et al. 1998). 
 
Even though in mammals only two ER subtypes have been characterized, the presence of three 
 
ER subtypes has been reported in teleosts including the zebrafish (Danio rerio) (Hawkins et al. 
2000; Ma et al. 2000; Menuet et al. 2002) Zebrafish ERα (esr1) is orthologous to the human ERα, 
while ERβ1 (esr2b) and ERβ2 (esr2a) are orthologs of the human ERβ (Bardet et al. 2002). The 
overall amino-acid sequence identity between the zfER subtypes and their corresponding human 
ER orthologs is approximately 50% (Menuet et al. 2002). Since these three zfERs are thought to 
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mediate different biological effects, there is an increased interest in finding subtype-selective 
zfER ligands. 
 
Xenoestrogens represent a class of endocrine disruptors that affect estrogen signaling. This class 
of compounds is composed of natural estrogens (phyto and mycoestrogens), and synthetically 
derived agents including certain pharmaceuticals, pesticides and industrial compounds used in 
consumer goods (Singleton et al. 2003). Zebrafish is a worldwide recognized vertebrate model to 
investigate the mode of action of endocrine disrupting chemicals (EDCs) and their reproductive 
and developmental effects (Segner et al. 2009). Studies on zebrafish have led to significant 
advances on the effect of EDCs on ER-regulated pathways through the use of zebrafish-specific 
in vitro and in vivo models (Menuet et al. 2002; Brion et al. 2012; Cosnefroy et al. 2012; Gorelik 
et al. 2014). Although all three zfERs subtypes can be activated by 17β-estradiol (E2), similarly 
to the mammalian ERs, it has been shown that the capacity of some compounds to 
transcriptionally activate the estrogen receptors differs between zebrafish and mammals. For 
instance, the phytoestrogen genistein and the benzophenones BP1, THB and BP2 which are 
selective human ERβ agonists (Escande et al. 2006; Molina-Molina et al. 2008) preferentially 
activate zfERα (Cosnefroy et al. 2012). However, a detailed analysis of similarities and 
differences  in  ligand  specificity  between  zfERs  and  hERs  remains  to  be  performed.  The 
evaluation of the activity and transcriptional profiles of known mammalian estrogenic ligands in 
the zebrafish model can provide additional information for the analysis of ER-mediated processes 
in this organism including disruption of these processes by xenoestrogens (Notch and Mayer. 
2011). 
 
The purpose of this study was to evaluate the effects of several known natural, environmental and 
pharmaceutical (anti)estrogenic compounds on the transcriptional activity of the three zfERs and 
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to compare the data with their activity on hERs. To address this challenge, zfERα, zfERβ1 and 
zfERβ2 reporter cell lines were established in the same cellular context as we previously used to 
create hERα and hERβ cell lines (Balaguer et al. 1999). In HeLa cells, which stably express an 
ERE-driven luciferase reporter (HELN cells), we expressed the full-length zfERα, zfERβ1 and 
zfERβ2, respectively. The resulting HELN-zfERs cell lines are useful tools for the analysis of the 
effects of estrogenic compounds on gene transactivation by the three zfERs, and also for the 
comparison of these effects to the results obtained on the hER orthologs. Since zebrafish is used 
as a model for the study of the effects of xenoestrogens in vivo, determining the transcriptional 
profiles of estrogenic compounds on the zfERs is crucial to support the zebrafish model for ER- 
related studies and their extrapolation to the mammalian system. 
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Materials and methods 
 
 
Materials 
 
 
Tissue culture plates used in this study came from Greiner Bio-one (Monroe, NC, USA), and 
media was purchased from Invitrogen (Grand Island, NY, USA). Luciferin (sodium salt) was 
purchased from Promega (Charbonnières, France). 17β-Estradiol (E2) (1,3,5 [10]-estratriene- 
3,17β-diol), 17α-Estradiol (17α-E2) (1,3,5 [10]-estratriene-3,17 α -diol), estrone (E1) (1,3,5[10]- 
estratriene-3-ol-17-one), estriol (E3) (1,3,5[10]-estratriene-3,16α,17β-triol), 17α-ethynylestradiol 
(EE2) (17α-ethynyl-1,3,5[10]-estratriene-3,17β-diol), genistein (40,5,7-trihydroxyisoflavone), 
benzophenone-2 (BP2) (2, 2’, 4, 4’-tetrahydroxybenzophenone), α-zearalanol, α-zearalenol, 4- 
tert-octylphenol and bisphenol A were purchased from Sigma-Aldrich (Saint-Quentin Fallavier, 
France).       4,4’,4’’-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)       trisphenol       (PPT),       2,3-bis(4- 
 
hydroxyphenyl)-propionitrile (DPN), WAY200070 (7-Bromo-2-(4-hydroxyphenyl)-1,3- 
benzoxazol-5-ol), FERB033 (2-Chloro-3'-fluoro-3,4'-dihydroxy-[1,1-biphenyl]-4-carboxaldehyde 
oxime),  ERB041  (7-Ethenyl-2-(3-fluoro-4-hydroxyphenyl)-5-benzoxazolol),  MPP 
dihydrochloride (1,3-Bis(4-hydroxyphenyl)-4-methyl-5--[4-(2-piperidinylethoxy)phenol]-1H- 
pyrazole dihydrochloride), PHTPP (1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2- 
piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride) and liquiritigenin were purchased from 
Tocris Bioscience (Minneapolis, MN, USA). Ferutinin was purchased from Santa Cruz 
Biotechnology Inc (Dallas, Texas, USA). 4-Hydroxytamoxifen (4OH-Tam) (1-[p- 
dimethylaminoethoxyphenyl]-1-(4-hydroxyphenyl)-2-phenyl-1-butene), ICI 182,780 (7α,17β- 
[9[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol) were obtained 
from Zeneca (Macclesfield, UK). Raloxifene (6-hydroxy-3-[4-[2-(1piperidinyl)ethoxy]phenoxy]- 
2-(4-hydroxy  phenyl)-benzothiophene) came  from  Eli  Lilly  (Indianapolis,  IN,  USA).  3,17- 
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Dihydroxy-19-nor-17α-pregna-1,3,5(10)-triene-21,16α-lactone,  named  16α-LE2  and  8- 
vinylestra-1,3,5(10)-triene-3,17β-diol, named 8β-VE2 is a kind gift of Peter Muhn from Research 
Laboratories of Schering AG (Berlin, Germany). Compounds were dissolved in dimethyl 
sulfoxide (DMSO) as 10-2 M stock solutions and successive dilutions were performed in cell 
culture  medium. The  final  DMSO  concentration never  exceeded 0.1%  (v/v)  of  the  culture 
medium. 
 
 
 
 
Cell lines 
 
 
HELN-zfERα, -zfERβ1 and -zfERβ2 reporter cell lines were established in a similar way as 
HELN-hERα and -hERβ cell lines (Balaguer et al. 1999). Briefly, HELN-zfERα, β1 and β2 cell 
lines cells were obtained by transfection of HELN cells (HeLa cells stably transfected with the 
ERE-βGlobin-Luc-SVNeo plasmid) (Balaguer et al. 1999) by the corresponding pSG5-puro 
plasmids (pSG5-zfERα-puro, pSG5-zfERβ1-puro and pSG5-zfERβ2-puro, respectively). Cells 
were selected by geneticin (G418, Sigma-Aldrich) and puromycin (Sigma-Aldrich) at the final 
concentration of 1 mg/mL and 0.5 µg/mL, respectively. The best responsive clones were selected 
based on both EC50 values and luciferase induction factors of E2. 
 
 
 
 
 
Cell culture conditions 
 
 
The HELN zfERs and hERs cell lines were cultured in phenol red-free Dulbecco’s Modified 
Eagle’s Medium/F12 (DMEM/F12) and supplemented with 5% dextran-coated charcoal-treated 
fetal  bovine  serum  (FBS-DCC)  and  1%  antibiotic  (penicillin/streptomycin)  in  a  5%  CO2 
humidified atmosphere at 37°C. Selection agents (geneticin 1 mg/ml and puromycin 0.25 µg/ml) 
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were maintained in the cell culture medium. Luciferase assays were performed in 5% FBS-DCC 
 
medium. 
 
 
 
 
 
 
zfERα, zfERβ1 and zfERβ2 transactivation assays 
 
 
The HELN-zfERs cell lines were seeded at a density of 80,000 cells per well in 96-well white 
opaque tissue culture plates (Greiner CellStar, USA). Compounds to be tested were added 8 h 
later, and cells were incubated with compounds at 28°C for 16 h.  Cells were maintained in the 
presence of ligands at 28°C because of the improved transactivation ability of the zfERs at this 
temperature. Experiments were performed in quadruplicates in at least two independent 
experiments. At the end of the incubation period, culture medium was replaced with medium 
containing 0.3 mM luciferin. Luciferase activity was measured for 2 s in intact living cells using 
a plate reader (PerkinElmer Luminometer, MA, USA). EC50 values were measured using 
GraphPad Prism software (version 5.04; Graphpad Software Inc., San Diego, CA, USA). hERα 
and hERβ1 transactivation assays were performed in a similar manner except for the incubation 
temperature with the ligands (37°C instead of 28°C). 
 
 
 
 
 
zfERs binding assays 
 
 
The HELN-zfERs cell lines were seeded at a density of 80,000 cells per well in 96-well white 
bottom clear tissue culture plates (Greiner CellStar, USA). [3H]-E2 3 nM in the presence or in the 
absence of non-radioactive E2 10 µM were added 8 h later, and cells were incubated at 28°C or 
37°C for 16h. At the end of the incubation period, unbound material was aspirated and cells 
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washed  three  times  with  PBS.  Then,  0.2  ml  of  LSC-cocktail  (Emulsifier-Safe,  Packard 
Bioscience) was added and [3H]-bound radioactivity was counted. Protein concentrations were 
measured by Bio-Rad protein assay and used to normalize bound radioactivity values expressed 
in dpm. Experiments were performed in quadruplicate in at least two independent experiments. 
 
 
 
 
 
Results 
 
 
Impact of the temperature on transcriptional activation of zfERs. 
 
 
Since the functionality of rainbow trout ER has been shown to be temperature-sensitive 
(Cosnefroy et al. 2009 ; Matthews et al. 2002), we first tested the ability of E2 to activate the 
zfERs at different temperatures, including a temperature relevant to the physiology of this 
organism. As seen in Fig. 1A, the EC50 value of E2 was lower at 28°C (0.077 nM) than at 31°C 
(0.266 nM), 34°C (0.433 nM) or 37°C (1.921 nM) for zfERα. Similarly, the EE2 EC50 value was 
lower at 28°C (0.061 nM) than at 31°C (0.127 nM), 34°C (0.19 nM) or 37°C (0.947 nM) (Fig. 
1B). EC50 of zfERβ1 and zfERβ2 cell lines were also sensitive to the température (Fig. 1C and 
 
1D). EC50 values for E2 and EE2 were 0.039 and 0.031 nM at 28°C and 0.714 and 0.673 nM at 
 
37°C for zfERβ1. EC50 values for E2 and EE2 were approximately 0.118 and 0.031 nM at 28°C 
and 1.554 and 0.197 nM at 37°C for zfERβ2. As we suspected that the increase in the EC50 
values was due to zfERs degradation, we measured protein level by saturation ligand binding 
assay with [3H-E2]. In HELN-zfER cells, zfER concentration was 8-fold lower at 37°C than 28°C 
(data not shown). 
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Effects of human endogenous estrogens on zfERs transcriptional activation 
 
 
The measured EC50 values for E2 indicates that E2 has a slight zfERβ1 selectivity relative to the 
other zfER subtypes in this cell context. The reported EC50 values for E2 is approximately 0.017 
nM  for  hERα  and  0.068  nM  for  hERβ  (Escande  et  al.  2006),  suggesting  that  E2  has 
approximately a  6-fold  higher  potency  to  transactivate luciferase gene  expression  in  hERα 
relative to its zebrafish counterpart. 17α-Ethynilestradiol (EE2), which has a 31-fold greater 
potency to transactivate the luciferase reporter gene in HELN-hERα compared to hERβ (Escande 
et al. 2006), demonstrated equal agonistic activities on all 3 zfERs with EC values of 0.061 nM 
for zfERα and 0.031 nM for both zfERβ isoforms (Table 1). 
 
We next evaluated the effects of the weak estrogenic stereoisomer of 17α-estradiol (17α-E2), 
estrone (E1) and estriol (E3), on zfER-mediated transcriptional activation (Fig. 2). These 
endogenous ligands have been shown to behave as full agonists in both of the human ERs with a 
slight ERα selectivity (Escande et al. 2006 and supplementary data Fig. S1A). The transcriptional 
profiles obtained by E1, E3 and 17α-E2 indicate that these estrogens have a stronger potency in 
transactivating zfERα compared to the zfERβ1 and zfERβ2 isoforms (Fig. 2 A, B, C). E1 and E3 
displayed similar potencies on zfERα (EC50 values of 1.7 and 0.55 nM, respectively), zfERβ1 
(EC50 values of 5.6 and 2.6 nM, respectively) and zfERβ2 (EC50 values of 12.1 and 8.5 nM, 
respectively). Among the endogenous estrogens tested, 17α-E2 showed the weakest agonistic 
activity with EC50s of 5.3, 24.7 and 45.1 nM for zfERα, zfERβ1 and zfERβ2, respectively. 
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Selectivity of natural estrogens on zfERs transcriptional activity 
 
We next analyzed the ability of myco and phytoestrogens to activate the zfERs (Fig. 3). The 
mycoestrogen α-zearalanol (α-zea) exhibited EC50 values of 0.176 nM for zfERα, 0.71 nM for 
zfERβ1 and 1.2 nM for zfERβ2, which conferred 4-fold and 6.8-fold higher potencies in 
transactivation assays for HELN-zfERα compared to the zfERβ cell lines (Fig. 3A). The other 
zearalanone analogues (zearalanone, β-zearalanol, zearalenone, α-zearalenol and β-zearalenol) 
presented a similar profile (zfERα potency > zfERβ1 potency ≥ β2 potency, supplementary data 
Fig. S2A and data not shown). The phytoestrogen genistein, which present a higher affinity for 
hERβ than for hERα (Escande et al. 2006; Molina-Molina et al. 2008), demonstrated greater 
affinity for zfERα and zfERβ2 relative to zfERβ1 (Fig. 3B). Genistein activated zfERα and β2 
with a 3.9-4.4 greater potency than zfERβ1 with EC50 values of 40, 50 and 260 nM for zfERα, 
zfERβ2 and zfERβ1, respectively. Liquiritigenin, another phytoestrogen with higher affinity for 
hERβ than for hERα (supplementary data Fig. S1D), activated zfERα with a 12 greater potency 
than zfERβ2 with EC50 values of 563 and 6805 nM for zfERα and zfERβ2, respectively, and did 
not activate zfERβ1 at all (table 1 and Fig. 3C). Finally, ferutinin, a phytoestrogen with similar 
affinity for hERα and hERβ but with different maximal activity (Table 1 and supplementary data 
Fig. S1E)  displayed similar maximal activity (100%) but different potency for the zfERs (EC50 
values of 8, 3.4 and 132 nM for zfERα, zfERβ1 and zfERβ2, respectively) (Table 1 and Fig 3.D). 
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Selectivity of environmental compounds on zfERs transcriptional activity 
 
 
We next analyzed the ability of known environmental estrogenic compounds to activate the 
zfERs (Fig. 4). Similarly to the human ERs (Delfosse et al. 2012), bisphenol A (BPA) acted as a 
partial agonist towards the 3 zfERs (Fig. 4A). BPA displayed greater affinity for zfERα than the 
zfERβ subtypes. The EC50 values of BPA were 599 nM, 1.894 µM and 3.823 µM for zfERα, 
zfERβ1 and zfERβ2, respectively (Table 1). The alkylphenol 4-tert-octylphenol (4t-OP) and the 
nonylphenol mixture  (NPm)  acted  as  partial  agonists  towards  zfERα  and  zfERβ2  and  full 
agonists towards zfERβ1 (supplementary data Fig. 4B and 4C). 4tOP and NPm displayed greater 
affinity towards zfERα and zfERβ2 relative to zfERβ1. The EC50 values of 4tOP and NPm were 
763 and 487 nM for zfERα, 2478 and 4225 nM for zfERβ1 and 1223 and 603 nM for zfERβ2. 
Benzophenone 2 (BP2), which present a higher affinity for hERβ than for hERα (Molina-Molina 
et al. 2008), demonstrated greater affinity for zfERα and zfERβ2 relative to zfERβ1 (Fig. 4D). 
BP2 presented a 3-fold higher potency towards zfERα and zfERβ2 compared to zfERβ1 (EC50 
values of approximately 251 nM and 233 for zfERα and β2 respectively, and 803 nM for β1). 
 
 
 
 
 
Selectivity of of pharmaceuticals on zfERs transcriptional activity 
 
We next evaluated the ability of synthetic ligands to activate transcription through the zfERs. The 
human ERα selective compound 3,17-dihydroxy-19-nor-17α-pregna-1,3,5(10)-triene-21,16α- 
lactone (16α-LE2), which has over 1000-fold selectivity in reporter gene activation through hERα 
than hERβ (Escande et al. 2006) also showed greater selectivity for its zebrafish ERα counterpart 
relative to the zfERβ isoforms (Fig. 4A). Among all the compounds tested, 16α-LE2 displayed 
the greatest zfERα selectivity with approximately 429 and 115-fold higher potencies to activate 
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transcription by zfERα compared to zfERβ1 and zfERβ2, respectively. The selective ERα 
selective compound 4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5--triyl)trisphenol (PPT) did not activate 
zfERα at all while it  partially activated zfERβ1 and zfERβ2 (Fig. 4B). Even though 8-vinylestra- 
1,3,5(10)-triene-3,17β-diol  (8βVE2)   and   2,3-bis(4-hydroxyphenyl)-propionitrile  (DPN)   are 
human ERβ selective agonists, these compounds showed better selectivity for zfERα than for the 
zfERβ isoforms (Fig. 4C and 4D). The EC50 values for 8βVE2 were 32, 188 and 113 nM for 
zfERα, zfERβ1 and zfERβ2, respectively (Table 1). Likewise, the EC50 values of DPN were 
21.7, 238 and 115 nM for zfERα, zfERβ1 and zfERβ2, respectively (Table 1). Similarly, other 
human ERβ selective agonists such as 7-bromo-2-(4-hydroxyphenyl)-1,3-ben-zoxazol-5-ol 
(WAY300070), 2-chloro-3'-fluoro-3,4'-dihydroxy-[1,-1-biphenyl]-4-carboxaldehyde oxime 
(FERB33) and 7-ethenyl-2-(3-fluoro-4-hydroxyphen-yl)-5-benzoxazolol (ERB041) displayed 
greater potencies for zfERα compared to zfERβ1 and zfERβ2 (Table 1 and supplementary data 
Fig. S2B-D). 
 
 
 
 
 
Effect of pharmaceutical antagonists on transcriptional activity 
 
The pharmaceutical anti-estrogenic compounds ICI 182,780, raloxifene, 4OH-tamoxifen (4OH- 
Tam) were tested in the HELN-zfERs and all displayed full antagonistic activity in the three zfER 
cell lines (Fig. 5A, B, C). No agonistic activity for these three anti-estrogens was observed in our 
experimental system  (data  not  shown).  ICI  182,780  showed  slight  preferential antagonistic 
activity towards zfERα (IC50 value of 3 nM) than the zfERβ cell lines (IC50 values of 14.7 nM 
and 28 nM for zfERβ1 and β2, respectively) (Fig. 5A). 4OH-Tam antagonistic potency was 
greater  for  zfERα  and  zfERβ1  (IC50  values  of  8.2  and  4.5nM  for  zfERα  and  zfERβ1, 
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respectively) than for zfERβ2 (IC50 value of 29.4 nM) (Fig. 5B). Raloxifene which has slight 
preferential antagonistic activity towards hERα (IC50 value of 0.62 nM) than the hERβ (IC50 
value of 12 nM) was a more powerful antagonist for zfERβ1, with a 4.1 and 9.7-fold greater 
potencies towards the zERβ1 subtype compared to zfERα or zfERβ2, respectively (IC50 values 
of 57, 13.8 and 134 nM for zfERα, zfERβ1 and zfERβ2, respectively) (Fig. 5C). 
 
Another compound tested for its effect on transcriptional inhibition on the HELN-zfERs was the 
hERα selective agonist and hERβ antagonist PPT. As shown in figure 5D, PPT displayed full 
antagonistic  activity  towards  zfERα  (IC50  value  of  261  nM)  and  it  was  able  to  partially 
antagonize estrogenic activation in the zfERβ cell lines with IC50 values of 854 and 326 nM for 
zfERβ1 and zfERβ2, respectively. Finally, antagonists with hERα (MPP) and hERβ (PHTPP) 
selectivity  were  tested  on  the  HELN-zfERs  reporter  cells.  MPP  presented  slight  zfERβ1 
selectivity and PHTPP behaved as zfERs pan-antagonist (Table 1 and supplementary data Fig. 
S2E-F). 
 
 
 
 
 
Structural analysis of zfERα selectivity 
 
To gain structural insights into the zfERα selectivity of 16α-LE2 in human and zebrafish ERs, we 
used the web-based server EDMon (Endocrine Disruptor Monitoring; 
http://atome2.cbs.cnrs.fr/AT2B/SERVER/ EDMon.html) (Delfosse et al. 2012) to model hERα 
 
and hERβ in complex with this ligand. The structural basis of the hERα and hERβ selectivity 
towards certain ligands has been associated with two amino acid differences in their ligand 
binding pockets. Indeed, L384 and M421 of hERα are replaced by M336 and I373 in hERβ, 
respectively (Fig. 7 and Manas et al., 2004). Superimposition of the 16α-LE2-bound hERα model 
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on the crystal structure of hERα in complex with E2 (PDB code 3UUD) showed that the phenol 
ring of 16α-LE2 occupies the same position as that of E2 and is engaged in a network of hydrogen 
bonds with E353 from helix 3 (H3) and R394 from H5 (Fig. 8A). On the other side of the ligand- 
binding pocket (LBP), it appears that the hydrogen bond observed between the 17-hydroxyl 
group of E2 and H524 (H11) is conserved in 16α-LE2. The difference between the two complexes 
resides in the lactone ring of 16α-LE2 which points towards M421 (H7) that must undergo a large 
conformational change to accommodate this additional group. In hERβ, the linear M421 is 
replaced by the branched residue Ileu 373 characterized by a much smaller intrinsic flexibility 
(Fig. 8B). As a consequence, I373 maintains the synthetic ligand in a position where it interacts 
unfavorably with M336 (H3). Therefore, 16α-LE2 adopts different positions in hERα and hERβ, 
the more constrained environment provided by the latter accounting for the weaker affinity of the 
ligand for this receptor subtype. The affinity values measured with the zebrafish receptors reflect 
the variations in the space constraints provided by the different combinations of residues in the 
three receptor subtypes. With H3 and H7 residues identical to those of the human receptor, zfERα 
interacts with 16α-LE2 with the highest affinity. The slight difference in the binding affinity of 
16α-LE2 for hERα and zfERα relies most likely on the replacement of L349 (H3) by a methionine 
residue (M317) (Fig. 7) and a possible loss of a favorable interaction provided by the branched 
but not by the linear residue (Fig. 8C). With a conserved isoleucine in H7 (I406) and a leucine 
residue in H3 (L369) (Fig. 7), zfERβ1 displays the most constrained LBP reflecting the weakest 
binding affinity for 16α-LE2. This receptor combines two large residues with low (isoleucine) and 
medium (leucine) flexibilities (Figure 8D). The replacement of I406 in H7 of zfERβ1 by a 
leucine residue (L391) (Fig. 7) in zfERβ2 provides a slight gain in LBP plasticity (Figure 8D), in 
agreement with the slightly better affinity of 16α-LE2 for the latter. 
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The inability of hERβ-selective phytoestrogens (genistein and liquiritigenin) and pharmaceuticals 
(8bv-E2,  DPN,  WAY300070,  FERB033  and  ERB041)  to  activate  the  zfERβ  isoforms  is 
explained by the mutation of a critical amino acid involved in genistein binding in hERβ. In all 
zfERs, the position homologous to hERβ M336 is occupied, as in hERα, by a leucine residue 
(Fig. 7)(Sassi-Messai et al. 2009). This anino acid change most likely accounts for the lack of 
obvious selectivity of the phytoestrogens towards the zfERβ subtypes. 
 
 
 
 
 
Discussion 
 
 
Screening of endogenous, environmental and synthetic ligands in the HELN-zfER cell lines 
showed that known mammalian ER ligands are also able to induce transcriptional activity of 
zebrafish  ER  subtypes.  This  study  allowed  us  to  assess  differences  in  the  potency  of  the 
estrogenic compounds among the three zfER subtypes, and compare their selectivity towards 
hERs using a similar human cellular context. The HELN-zfERs cells were incubated at 28°C 
after addition of chemicals to the cells because it is a more physiologically relevant temperature 
for zebrafish, which increased the potency of estradiol approximately 10-fold compared to 
incubation at 37°C (Fig. 1). Temperature sensitivity of fish ERs has already been reported using 
reporter gene assays (Cosnefroy et al. 2009; Matthews et al. 2002) and the reason seems to be 
thermo-dependence of estrogen binding (Matthews et al. 2002; Sumida et al. 2003; Tan et al. 
1999). Interestingly, this thermo-dependence is not shared by other zebrafish nuclear receptors 
like the peroxisome proliferator activated receptor γ (Riu et al. 2014). 
Results from this study demonstrated that the selectivity of some of the tested compounds on 
 
zfERs differs from that observed between hERα and hERβ orthologs. zfERα and zfERβs belong 
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to the ERα and ERβ phylogenetic groups, respectively; however, one to three amino-acids  differ 
in the ligand binding domain of the zfERs compared to their human ER counterparts (Table 3), 
which  certainly  explains  the  differences  in  selectivity  and  sensitivity  of  estrogenic  ligands 
between zebrafish and human ERs. 
 
Among the natural estrogens tested in the HELN-zfER cell lines, 17β-estradiol (E2) was the 
compound with the highest potency towards the three zfERs, followed by estriol (E3), estrone 
(E1) and 17α-E2. Likewise, a study using transiently-transfected HEK293 cells showed that E2 
was the most potent endogenous ligand for zfERα with EC50 of 0.177 nM, very similar to the 
EC50 value of E2 for zfERα in our study (0.077 nM) (Lange et al. 2012). E2 also is the 
endogenous compound with the highest affinity for the hERs, and it also displays a better affinity 
for hERα (Escande et al. 2006). The zfERs were less sensitive to E2 than hERs, with 
approximately 6 and 2-fold lower transactivation potencies for the zfERα and zfERβ subtypes 
relative to their human orthologs, respectively. 
Among  the  myco  and  phytoestrogens, α-zearalanol (α-zea)  demonstrated the  best  agonistic 
activity via the zfERα and zfERβ forms with the ability to almost fully activate the luciferase 
reporter at relative low EC50 values. α-zea preferentially activated zfERα in the HELN-zfERs, 
which is in accordance with our previous studies performed in zebrafish liver-derived cell lines 
(Cosnefroy et al. 2012). The phytoestrogen genistein, a full agonist in both human ERs with 10- 
fold higher selectivity for hERβ, showed preferential and equal activity towards zfERα and 
zfERβ2 over zfERβ1. This phytoestrogen also behaved as a full agonist in the zebrafish cell lines, 
and displayed slightly higher affinity for zfERα and zfERβ2 than for zfERβ1 (Cosnefroy et al. 
2012). Similar transactivation properties by genistein were observed in HeLa cells transiently 
 
transfected with the zfERs and an estrogen-dependent luciferase reporter (Sassi-Messai et al. 
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2009). Liquiritigenin, another phytoestrogen with higher hERβ then hERα affinity, also displayed 
preferential and equal activity towards zfERα and zfERβ2 over zfERβ1. Finally, ferutinin, a 
terpenoid with similar affinity for hERα and hERβ but different activity (full agonist on hERα 
and partial agonist on hERβ) (Ikeda et al. 2002), behaved as a full agonist on the three zfERs and 
displayed slightly higher affinity for zfERα and zfERβ1 than for zfERβ2. 
 
Among environmental pollutants, bisphenol A (BPA) also presented higher affinity for zfERα 
 
relative to the zfERβ subtypes. Accordingly, in the zebrafish-derived cell lines (Cosnefroy et al. 
 
2012), BPA also displayed better potency towards zfERα. Considering reporter gene activation in 
the human ERs, BPA displays similar agonistic properties between hERα and hERβ, presenting 
slightly better efficacy towards hERβ (Delfosse et al. 2012). The alkylphenols 4tOP and NPm 
also  showed  better  potency  towards  zfERα  than  the  zfERβ  subtypes.  The  benzophenone 
derivative BP2 behaved as a full agonist in the three zfERs, with similar EC50s for both zfERα 
and zfERβ2. Cosnefroy et al. (2012) also found that BP2 has a slightly higher activity towards 
zfERα, with approximately 1.36 and 2 fold- higher potencies compared to zfERβ2 and β1, 
respectively (Cosnefroy et al. 2012). 
 
17α-EE2 was the pharmaceutical compound that displayed the highest affinity towards the zfERs, 
with almost equivalent potencies in transactivating the three zfER subtypes. Similarly to hERs, 
16α-E2, which has 1000-fold selectivity for hERα (Escande et al. 2006), also exhibited higher 
affinity for zfERα compared to the zfERβ subtypes (approximately 100 and 370-fold higher 
potencies than zfERβ2 and zfERβ1, respectively) and it is the most selective compound for 
zfERα found in this chemical screening. Conversely, PPT, another hERα selective agonist that is 
unable to activate hERβ (Escande et al. 2006), was devoid of agonistic activity in the HELN- 
zfERα cells, and instead behaved as an antagonist to zfERα, while it slightly activated the zfERβ 
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subtypes. IC50 values obtained in zfERs cells indicated that PPT displayed preferential affinity 
for zfERα than for zfERβ (Table 2 and Fig. 7). Similarly to phytoestrogens, known human ERβ 
selective synthetic agonists, such as DPN, 8β-VE2, FERB033, ERB033 and WAY200070 
preferentially activated zfERα. 
 
A recent study reported differences in ER subtype tissue localization in the developing zf larvae: 
zfERα is selectively expressed in the heart valves, zfERβ2 is robustly expressed in the liver, 
whereas  zfERβ1  is  not  detected  (Gorelik  et  al.  2014).  In  this  same  study,  treatment  of  a 
transgenic zebrafish model containing a 5x consensus ERE sequence upstream of a GFP reporter 
(5xERE:GFP) with genistein, BPA and DPN preferentially induced GFP expression in the heart 
valves. PPT, on the other hand, showed GFP labeling of only the larval liver. Our study confirms 
the in vivo findings that these compounds present opposite selectivity of what has been observed 
for the human ER subtypes. Moreover, as the selectivity of several ligands is not conserved 
between human and zf ER subtypes, the determination of the transcriptional profile of estrogenic 
compounds towards the zfERs is crucial before their use in vivo to help elucidate distinct roles of 
each ER subtype in zf. 
 
The hERs pan-antagonists ICI 182,780, 4-OH tamoxifen all acted as pure antagonists in the three 
zfERs. ICI 182,780 presented slight zfERα selectivity while 4-OH tamoxifen antagonized more 
efficiently zfERβ1 and zfERα than zfERβ2. In accordance with our results, ICI 182,780 blocks 
EE2-mediated transcriptional activation with all three isoforms of the zfERs in MDA-MB-231 
cells transiently transfected with the zfERs (Notch and Mayer ; 2011). In vivo, treatment of 
zebrafish larvae with either ICI 182,780 or 4-OH tamoxifen reduce the E2-induced fluorescence 
in liver of transgenic 5XERE:GFP zebrafish (Gorelik and Halpern. 2011). Althrough ICI 182,780 
has a higher antagonistic activity towards zfERα compared to zfERβ2 and β1, ICI 182,780 is also 
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efficient in reducing or blocking the GFP induced by various estrogens and pro-estrogens in the 
brain  of  cyp19a1b-GFP larvae (Brion  et  al.  2012).  The  hERα (raloxifen, MPP)  and  hERβ 
selective (PHTPP) antagonists were also tested on the HELN-zfERs reporter cells. Slight zfERα 
selectivity  was  also  observed  for  PHTPP  whereas  raloxifen  and  MPP  antagonized  more 
efficiently zfERβ1 than zfERα and zfERβ2. Thus, there is also a non-conserved selectivity 
between zfERs and their human orthologs for antiestrogens. 
 
To conclude, we have shown here that there are clear differences between the selectivity of 
various (anti)estrogens for zebrafish and human ER isoforms, establishing the fact that a direct 
translation of (anti)estrogenic effects (activities or potencies) from mammals to zebrafish is not 
possible. Although none of the tested compounds specifically activated either zebrafish or human 
ERs, the differences revealed in this study in terms of transcriptional activities towards human 
and zebrafish ERs highlight the need to take into account i) the species of origin and ii) the ER 
subtype when assessing the estrogenic potency of chemicals. This is particularly important in 
regards to EDCs screening for hazard assessment, since at the present time established test 
guidelines are only based on human cell lines expressing human estrogen receptors. To this end, 
such newly established in vitro cell lines together with those previously established in ZFL cells 
(Cosnefroy et al. 2012) can serve as useful screening tools to address estrogenic potency of 
chemicals for piscine models. Hence, an initial screening should be followed up with an ER- 
subtype specific analysis using both human and zebrafish ERs to elucidate the full spectrum of 
ER-mediated xenoestrogens effects. 
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Figure legends 
 
 
Figure 1. Zebrafish ERs are thermosensitive. Transcriptional activity of zfERα in response to 
different concentrations of E2 (A) and EE2 (B) was measured at 28, 31, 34 and 37°C. 
Transcriptional activity of zfERβ1 (C) and zfERβ2 (D) in response to E2 and EE2 were measured 
at 28 and 37°C. Results are expressed as % 10 nM E2. Standard deviations are from independent 
experiments done in quadruplicate. 
 
 
Figure 2. Transcriptional activity of zfERα, zfERβ1 and zfERβ2 in response to endogenous 
estrogens. HELN-zfERα (  ), HELN zf-ERβ1 (  ), HELN-zfERβ2 (○) cells were exposed to 
different concentrations of E1, E3 and 17αE2. Results are expressed as % of 10 nM E2 treatment. 
Standard deviations from at least 2 independent experiments done in quadruplicate are indicated. 
 
 
Figure 3. Transcriptional activity of zfERα, zfERβ1 and zfERβ2 in response to myco and 
phytoestrogens. HELN-zfERα (   ), HELN zf-ERβ1 (  ), HELN-zfERβ2 (○) cells were exposed 
to different concentrations of α-zea, genistein, liquiritigenin and ferutinin. Results are expressed 
as % of 10 nM E2 treatment. Standard deviations from at least 2 independent experiments done 
in quadruplicate are indicated. 
 
Figure 4. Transcriptional activity of zfERα, zfERβ1 and zfERβ2 in response to environmental 
estrogens. HELN-zfERα (  ), HELN zf-ERβ1 (  ), HELN-zfERβ2 (○) cells were exposed to 
different concentrations of BPA, 4-tet-octylphenol, NPm and BP2. Results are expressed as % of 
 
10 nM E2 treatment. Standard deviations from at least 2 independent experiments done in 
quadriplicate are indicated. 
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Figure 5. Transcriptional activity of zfERα, zfERβ1 and zfERβ2 in response to pharmaceuticals. 
HELN-zfERα (  ), HELN zf-ERβ1 (  ), HELN-zfERβ2 (○) cells were exposed to different 
concentrations of 16αLE2, PPT, 8βVE2 and DPN. Results are expressed as % of 10 nM E2 
treatment. Standard deviations from at least 2 independent experiments done in quadruplicate are 
indicated. 
 
 
 
Figure 6. Transcriptional activity of zfERα, zfERβ1 and zfERβ2 in response to synthetic 
antagonists. HELN-zfERα (   ), HELN zf-ERβ1 (  ), HELN-zfERβ2 (○) cells were exposed to 
different concentrations of ICI 182,780, 4OH-Tamoxifen, raloxifen and PPT together with 1 nM 
E2. Results are expressed as % of E2 treatment. Standard deviations from at least 2 independent 
experiments done in quadruplicate are indicated. 
 
Figure 7. Amino acid alignment of human ERβ and zebrafish ERs ligand binding domains 
(LBDs) with par of the human ERα LBD (Met 342 to Ileu 426). The three amino acids involved 
in the binding of estrogens which differed betwen ERs are framed. Numbers above the human 
sequences indicate the number of amino acid residue within the total human ERα and ERβ 
sequences. The GenBank accession numbers of the ER sequences in this alignment are : human 
ERα NP_000116;   human   ERβ NP_001428;   zebrafish   ERα   NP_694491;   zebrafish   ERβ1 
 
CAC93848.1 and zebrafish ERβ2 CAC93849.1. 
 
 
 
 
Figure 8. Modeling of the interaction between 16α-LE2  and the human (h) and zebrafish (zf) 
estrogen receptors. Superposition of the structures of hERα (A) and hERβ (B) LBDs bound to E2 
(green) onto the molecular models of the 16α-LE2-bound hERα (A) and 16α-LE2-bound hERβ 
(B) LBDs (yellow). In hERα, the lactone ring of 16α-LE2 points towards M421 (H7) which 
undergoes a large conformational change (black arrow) to accommodate this additional group. In 
hERβ, the linear M421 is replaced by the branched residue I373 which is characterized by a 
much smaller intrinsic flexibility that maintains the synthetic ligand in a position (black arrow) 
where it interacts unfavorably with M336 (H3, red asterisk). Key hydrogen bonds between the 
protein and the ligands are highlighted by doted lines. W denote a water molecule. Superposition 
of the structures of hERα (C) and hERβ (D) LBDs bound to E2 (green) onto the molecular models 
of the 16α-LE2-bound zfERα (C) and 16α-LE2-bound zfERβ1 or zfERβ2 (yellow and violet, 
respectively) (D) LBDs. The steric constrains observed in hERs also apply to zfERs and account 
for the differential affinity of 16α-LE2  for the zfER subtypes. In (C) the doted line highlight a 
stabilizing interaction between hERα and the ligand that is probably missing in zfERα. 
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